Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023)
Inhibikase Therapeutics' (IKT) quarterly Change in Receivables came in at -$79602.0 in Q3 2023, down 1191.93% year-on-year from $7290.0 in Q3 2022, and down 627.76% on a QoQ basis from $15083.0 in Q2 2023.
Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has 3 years of Change in Receivables data on file, last reported at -$79602.0 in Q3 2023.
- On a quarterly basis, Change in Receivables fell 1191.93% year-over-year to -$79602.0 in Q3 2023; TTM through Jun 2024 was -$79602.0, a 143.45% decrease from a year earlier, with the FY2023 full-year figure at -$39881.0, down 200.0% from the prior year.
- Change in Receivables for Q3 2023 stood at -$79602.0, down from $15083.0 in the prior quarter.
- Over the last five years, Change in Receivables for IKT reached as high as $332774.0 in Q1 2021 and fell as low as -$369099.0 in Q3 2021.
- Historically, Change in Receivables has averaged $10012.8 across 3 years, with a median of $7290.0 in 2022.
- Across the five-year window, Change in Receivables soared 226.87% in 2022 and sank 1191.93% in 2023, its largest moves.
- Year by year, Change in Receivables stood at -$107341.0 in 2021, then surged by 226.87% to $136180.0 in 2022, then slumped by 158.45% to -$79602.0 in 2023.
- Per Business Quant data, the three most recent Change in Receivables figures were -$79602.0 in Q3 2023, $15083.0 in Q2 2023, and $24638.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -79,602.00 |
| Sep 30, 2023 | -79,602.00 |
| Jun 30, 2023 | 15,083.00 |
| Jun 30, 2023 | 15,083.00 |
| Mar 31, 2023 | 24,638.00 |
| Mar 31, 2023 | 24,638.00 |
| Dec 31, 2022 | 136,180.00 |
| Dec 31, 2022 | 136,180.00 |
| Sep 30, 2022 | 7,290.00 |
| Sep 30, 2022 | 7,290.00 |
| Jun 30, 2022 | -41,424.00 |
| Jun 30, 2022 | -41,424.00 |
| Mar 31, 2022 | -62,165.00 |
| Mar 31, 2022 | -62,165.00 |
| Dec 31, 2021 | -107,341.00 |
| Dec 31, 2021 | -107,341.00 |
| Sep 30, 2021 | -369,099.00 |
| Sep 30, 2021 | -369,099.00 |
| Jun 30, 2021 | 253,807.00 |
| Jun 30, 2021 | 253,807.00 |